Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Takeda, Portal Instruments Ink $100M Deal to Develop Needle-Free Drug Delivery Device

  • Post author:Sam
  • Post published:November 6, 2017
  • Post category:BioPharma

Takeda inked a collaboration deal to develop and commercialize Portal's needle-free drug delivery device for use with some of Takeda's biologic medicines. Source: BioSpace

Continue ReadingTakeda, Portal Instruments Ink $100M Deal to Develop Needle-Free Drug Delivery Device

Confident Bristol-Myers to Launch 700-Patient Phase III IDO Trial for Melanoma

  • Post author:Sam
  • Post published:November 6, 2017
  • Post category:BioPharma

Bristol-Myers is initiating a Phase III clinical trial of BMS-986205 with nivolumab in patients with advanced melanoma. Source: BioSpace

Continue ReadingConfident Bristol-Myers to Launch 700-Patient Phase III IDO Trial for Melanoma

Counsyl Celebrates Anniversary With $80M Funding Round

  • Post author:Sam
  • Post published:November 6, 2017
  • Post category:BioPharma

The increased funding showcases investor confidence in Counsyl’s leading genetic screening products and business model. Source: BioSpace

Continue ReadingCounsyl Celebrates Anniversary With $80M Funding Round

Varian Inks $50M Multi-Year Project Deal

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

Varian said it will replace linear accelerators in the oncology departments of Rigshospitalet and Herlev Hospital with 15 advanced Varian TrueBeam and Halcyon treatment machines and two ViewRay MRIdian MR-Guided…

Continue ReadingVarian Inks $50M Multi-Year Project Deal

Gates and His Rich Buddies Back Exicure's $11.2M Funding Round

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

Exicure announced it had closed on $11.2M in private financing. Source: BioSpace

Continue ReadingGates and His Rich Buddies Back Exicure's $11.2M Funding Round

Valeant Sells Sprout Pharma to a New Company 'Associated' With Sprout Founders

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi. Source: BioSpace

Continue ReadingValeant Sells Sprout Pharma to a New Company 'Associated' With Sprout Founders

Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

Shares of Teva are up more than 5 percent this morning after Israeli media reported billionaire businessman Len Blavatnik is considering taking a large stock position in the pharma giant.…

Continue ReadingBillionaire Businessman Looking to Take Stake in Debt-Ridden Teva

Two-Year Old Biotech NousCom Nabs $49M to Fund New Drug Into Clinic

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

The round was led by new investor Abingworth with participation from another new investor, 5AM Ventures, LSP and Versant Ventures. Source: BioSpace

Continue ReadingTwo-Year Old Biotech NousCom Nabs $49M to Fund New Drug Into Clinic

TherapeuticsMD Soars on Plans to Resubmit TX-004HR NDA Without New Pre-Approval Study

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

Shares of TherapeuticsMD have shot up more than 51 percent in morning trading after the FDA reversed course on its rejection of that company's vaginal pain medication. Source: BioSpace

Continue ReadingTherapeuticsMD Soars on Plans to Resubmit TX-004HR NDA Without New Pre-Approval Study

The Battle Between Two $1B+ Biotech Unicorns

  • Post author:Sam
  • Post published:November 5, 2017
  • Post category:BioPharma

Two of the top companies in the field are German-based CureVac and U.S.-based Moderna Therapeutics. Source: BioSpace

Continue ReadingThe Battle Between Two $1B+ Biotech Unicorns
  • Go to the previous page
  • 1
  • …
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company